Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29.

Authors

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
³ Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
⁵ Department of Pathology, University of Iowa, Iowa City, IA, USA.

No abstract available

Keywords: central nervous system relapse; clinical trials; lymphomas.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Central Nervous System Neoplasms / etiology
Central Nervous System Neoplasms / therapy*
Female
Follow-Up Studies
Humans
Immunotherapy, Adoptive / methods
Lymphoma, Large B-Cell, Diffuse / complications
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / therapy*
Male
Middle Aged
Progression-Free Survival
Recurrence
Young Adult

Grants and funding